Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
CB307
DRUG
2 trials
Sponsors
Crescendo Biologics Ltd.
Conditions
Advanced and/or Metastatic Solid Tumours
Phase 1
Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.
NCT04839991
Crescendo Biologics Ltd.
Advanced and/or Metastatic Solid Tumours
Start: 2021-06-08
End: 2024-09-25
Target: 70
Updated: 2023-11-18
A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions
Active, not recruiting
NCT05836623
Crescendo Biologics Ltd.
Advanced and/or Metastatic Solid Tumours
Start: 2022-12-20
End: 2024-10-31
Updated: 2024-02-28
Related Papers
Solving selectivity issues in LBAs: case study using Gyrolab to quantify CB307, a bispecific Humabody in human serum
Bioanalysis
2024-07-03
2 citations
Abstract 1807: CB307: a novel targeted CD137 agonist for enhancement of immune cell responses to PSMA+ tumors
Cancer Research
2023-04-04
1 citations
Abstract 2877: CB307: A novel selective CD137 agonist for enhancement of immune cell responses to PSMA+ tumors
Cancer Research
2022-06-15
1 citations
Abstract CT207: A phase 1 open-label, dose escalation and expansion trial to investigate the safety, pharmacokinetics and pharmacodynamics of CB307, a Trispecific Humabody® T-cell enhancer, in patients with PSMA+ advanced and/or metastatic solid tumors (POTENTIA)
Cancer Research
2022-06-15
1 citations